Other Events ·
AIM ImmunoTech Inc. entered into a Proposal Agreement with Sterling Pharma Solutions on July 31, 2026, to manufacture…
AIMIAIM ImmunoTech Inc.
AIM ImmunoTech Inc. entered into a Proposal Agreement with Sterling Pharma Solutions on July 31, 2026, to manufacture batches of PolyI and Poly C12U drug substances and transfer associated test methods at the manufacturer's UK facility. The estimated cost is approximately $1.5 million payable over 12 months, with products intended for ongoing clinical trials and a potential Phase 3 trial for metastatic pancreatic cancer. The filing also discloses notice deadlines for director nominations for the 2026 annual meeting. AIM ImmunoTech Inc. operates in the biotechnology industry, focusing on immunotherapy treatments.